MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...
MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions to flesh out its pipeline, according to chief executive Rob Davis. On the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback